NASDAQ: BFRIBiofrontera Inc Stock
$0.98+0.02 (+2.08%)
Updated Oct 15, 2025
BFRI Price
$0.98
Fair Value Price
N/A
Market Cap
$10.48M
52 Week Low
$0.54
52 Week High
$2.22
P/E
-0.53x
P/B
-2.24x
P/S
0.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$39.19M
Earnings
-$16.59M
Gross Margin
59%
Operating Margin
-41.64%
Profit Margin
-42.3%
Debt to Equity
-5.32
Operating Cash Flow
-$9M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BFRI Overview
Biofrontera Inc. is a biopharmaceutical company focused on the treatment of dermatological conditions. The company offers Ameluz, a prescription drug approved for use in combination with the company's licensor's medical device. Its RhodoLED lamp series is used to provide photodynamic treatment of mild-to-moderate actinic keratosis of the face and scalp. Biofrontera also provides Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 1997 and is headquartered in Woburn, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BFRI's potential to beat the market
- BFRI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BFRI
RankedUnranked of 58
RankedUnranked of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.78 | A | |
| $90.10 | A | |
| $25.19 | A |
Be the first to know about important BFRI news, forecast changes, insider trades & much more!
BFRI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BFRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BFRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BFRI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BFRI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BFRI due diligence checks available for Premium users.
Valuation
BFRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.53x
Industry
-51.88x
Market
37.33x
BFRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.24x
Industry
2.22x
BFRI's financial health
Profit margin
Revenue
$9.0M
Net Income
-$5.3M
Profit Margin
-59%
BFRI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BFRI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.1M
Liabilities
$24.8M
Debt to equity
-5.32
BFRI's short-term liabilities ($19.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BFRI's short-term assets ($18.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BFRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BFRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
-$1.0k
Financing
$8.5M
BFRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BFRI vs Pharmaceutical Stocks
Biofrontera Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.